Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Viruses - 14(2022), 9 vom: 13. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Basile, Kerri [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.09.2022 Date Revised 05.10.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/v14092023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346632021 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346632021 | ||
| 003 | DE-627 | ||
| 005 | 20231226031921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/v14092023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346632021 | ||
| 035 | |a (NLM)36146829 | ||
| 035 | |a (PII)2023 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Basile, Kerri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.09.2022 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a Pfizer-BioNTech BNT162b2 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a VOC | |
| 650 | 4 | |a immunity | |
| 650 | 4 | |a neutralising antibodies | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Viral Envelope Proteins |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Rockett, Rebecca J |e verfasserin |4 aut | |
| 700 | 1 | |a McPhie, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Fennell, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson-Mackinnon, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Agius, Jessica E |e verfasserin |4 aut | |
| 700 | 1 | |a Fong, Winkie |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Hossinur |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Donavan, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Hueston, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Connie |e verfasserin |4 aut | |
| 700 | 1 | |a Arnott, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Sharon C-A |e verfasserin |4 aut | |
| 700 | 1 | |a Maddocks, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a O'Sullivan, Matthew V |e verfasserin |4 aut | |
| 700 | 1 | |a Dwyer, Dominic E |e verfasserin |4 aut | |
| 700 | 1 | |a Sintchenko, Vitali |e verfasserin |4 aut | |
| 700 | 1 | |a Kok, Jen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 14(2022), 9 vom: 13. Sept. |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:9 |g day:13 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/v14092023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 9 |b 13 |c 09 | ||